OKYO Pharma's Mid-Stage Eye Pain Trial Shows Improved Quality-of-Life Outcomes with Urcosimod

OKYO Pharma reported improved quality-of-life outcomes in a mid-stage trial of its experimental therapy urcosimod for neuropathic corneal pain. Patients treated with urcosimod showed greater improvements in emotional well-being, daily functioning, and pain relief compared to placebo. The findings will be presented at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology. OKYO plans to advance the therapy into larger confirmatory studies to further evaluate its efficacy and safety.